HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial

Journal of the International Association of Providers of AIDS Care
Cassidy W ClaassenAnthony Amoroso

Abstract

Characterizing viral response to lopinavir/ritonavir (LPV/r) monotherapy as second-line treatment may guide recommendations for resource-limited settings (RLS). We conducted a 48-week prospective, single-arm study of LPV/r monotherapy in patients failing first-line therapy in Nigeria. The primary outcome was sustained HIV-1 viral load (VL) <400 copies/mL at 48 weeks. Of 30 enrolled patients, 28 (93%) achieved viral suppression on LPV/r, while 29 (96%) experienced low-level viremia. At 48 weeks, 9 (30%) met the primary outcome of sustained viral suppression; 14 (47%) patients were suppressed on LPV/r in a snapshot analysis. Detectable VLs at 12 and 24 weeks were strongly associated with treatment failure at 48 weeks. New resistance mutations were not detected. The trial was stopped early due to treatment failure. In this study, the rate of virologic failure among patients on a second-line lopinavir monotherapy regimen was relatively high and predicted by early detectable viremia. However, no LPV/r-associated resistance mutations were detected despite fluctuating low-level viremia, demonstrating the high genetic barrier to resistance of the protease inhibitor class which could be useful in RLS.

References

Oct 18, 2000·Journal of Acquired Immune Deficiency Syndromes : JAIDS·A MocroftA N Phillips
Aug 24, 2007·The Journal of Antimicrobial Chemotherapy·Emanuele NicastriMassimo Andreoni
Nov 9, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Habib O RamadhaniJohn A Crump
Jul 11, 2008·PLoS Medicine·Olivia KeiserUNKNOWN Swiss HIV Cohort Study (SHCS) and the International Epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA)
Aug 19, 2008·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Marco FloridiaStefano Vella
Dec 31, 2008·AIDS·Wouter F W BiermanCharles A B Boucher
Sep 17, 2010·The Journal of Antimicrobial Chemotherapy·Jean-Luc MeynardUNKNOWN KALESOLO Study Group
Sep 16, 2011·The Journal of Infectious Diseases·Sidonie Lambert-NiclotAnne-Genevieve Marcelin
Jul 21, 2012·Antiviral Therapy·Charles F GilksUNKNOWN DART Virology Group and Trial Team
May 30, 2013·Antimicrobial Agents and Chemotherapy·Luis F Lopez-CortesPompeyo Viciana
Sep 10, 2013·International Journal of STD & AIDS·Jose ArribasChristiane Moecklinghoff
Jul 12, 2014·The New England Journal of Medicine·Nicholas I PatonUNKNOWN EARNEST Trial Team
Nov 14, 2014·Journal of the International AIDS Society·Andrea AntinoriAndrew Hill
Nov 15, 2014·Journal of the International AIDS Society·Jose ArribasMaria Blanca Hadacek
Nov 15, 2014·Journal of the International AIDS Society·Juan PasquauCarmen Hidalgo-Tenorio
Dec 11, 2014·Journal of the International AIDS Society·Brooke E NicholsDavid A M C van de Vijver
Oct 2, 2015·The Lancet. HIV·Nicholas I PatonUNKNOWN Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team
Mar 12, 2016·PharmacoEconomics·Lars OddershedeUNKNOWN Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) Trial Team
Feb 14, 2017·PloS One·Nicola GianottiUNKNOWN Icona Foundation Study and mono-PI/r database Study Cohorts

❮ Previous
Next ❯

Software Mentioned

Stata

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.